Results 141 to 150 of about 394,535 (329)
"Deficit Problem with the Fourth Industrial Revolution "
Sh. Sachin Gupta
openalex +1 more source
The future of work: Towards a progressive agenda for all. EPC Issue Paper 9 DECEMBER 2019 [PDF]
Europe’s labour markets and the world of work in general are being transformed by the megatrends of globalisation, the fragmentation of the production and value chain, demographic ageing, new societal aspirations and the digitalisation of the economy ...
Dhéret, Claire +2 more
core
ABSTRACT This study analyzed Industry 4.0 (I4.0) technology applications in agribusiness and the role of strategic stakeholders, engagement methods, and other critical aspects data sharing, confidentiality, integrity, decision‐making, and sector‐specific requirements in promoting circularity.
Simone Sehnem +3 more
wiley +1 more source
New Psychoactive Substances and evolving criminal dynamics against the backdrop of the fourth industrial revolution. [PDF]
Zaami S.
europepmc +1 more source
ABSTRACT Although artificial intelligence (AI) is increasingly being touted to assist organizations, AI integration for sustainability efforts has been limited AND sporadic and tends to follow an ad hoc strategy. The existing literature therein focuses on the technological capabilities of AI, overlooking how organizations make sense of and ...
Amanda Balasooriya, Darshana Sedera
wiley +1 more source
An Exploratory Study and Impact of Fourth Industrial Revolution (4IR) on SMEs in the Middle East
Hanin Suleiman Alqam, Mohammed Saqib
openalex +1 more source
Emerging trends and opportunities for industry 4.0 development in Russia [PDF]
The fourth industrial revolution is the blending of technologies of the physical, digital and biological world, which creates new opportunities and affects political, social and economic systems. The fourth industrial revolution fundamentally transforms
Finogeev, A. +4 more
core
Abstract Artificial intelligence and automation are no longer just buzzwords in the biopharmaceutical industry. The manufacturing of a class of biologics, comprising monoclonal antibodies, cell therapies, and gene therapies, is far more complex than that of traditional small molecule drugs.
Shyam Panjwani, Hao Wei, John Mason
wiley +1 more source

